Spiriva Positive Cmte. Vote Reflects FDA Advisors’ Comfort With Ambiguous Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim’s tiotropium spray gets strong support at Pulmonary-Allergy Drugs Advisory Committee meeting, with lingering safety concerns dismissed as “statistical weeds.”